Reaction
Meningitis Viral reporting signals
As of the last recalculation, Meningitis Viral appears in 1,360 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is GANCICLOVIR SODIUM (PRR 35.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ganciclovir Sodium | 24 | 35.3 | 35.4 |
| Ganciclovir | 23 | 35.0 | 35.0 |
| Valganciclovir Hydrochloride Powder, | 22 | 28.0 | 28.1 |
| Alemtuzumab | 30 | 24.3 | 24.3 |
| Sirolimus | 19 | 21.9 | 21.9 |
| Anakinra | 23 | 21.6 | 21.6 |
| Valganciclovir | 24 | 19.8 | 19.8 |
| Valganciclovir Hydrochloride | 24 | 19.8 | 19.8 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 12 | 18.4 | 18.4 |
| Efavirenz | 13 | 18.0 | 18.0 |
| Zidovudine | 11 | 12.7 | 12.7 |
| Darunavir | 11 | 11.2 | 11.2 |
| Ritonavir 100 Mg | 10 | 10.3 | 10.3 |
| Fludarabine Phosphate | 24 | 9.5 | 9.5 |
| Brentuximab Vedotin | 6 | 9.0 | 9.0 |
| Agalsidase Beta | 5 | 8.3 | 8.3 |
| Cladribine | 5 | 8.0 | 8.0 |
| Ocrelizumab | 28 | 7.0 | 7.0 |
| Palivizumab | 7 | 7.0 | 7.0 |
| Eculizumab | 20 | 5.7 | 5.7 |
| Ravulizumab | 5 | 5.7 | 5.7 |
| Axicabtagene Ciloleucel | 3 | 4.7 | 4.7 |
| Ofatumumab | 10 | 4.6 | 4.6 |
| Natalizumab | 49 | 4.2 | 4.2 |